Beating forecasts and raising guidance is not always enough to please investors, and GSK plc is a case in point. Despite a broadly successful second quarter, the group’s stock dipped by 2% in early trade on 31 July.
Key Takeaways
- GSK reported higher than expected Q2 revenues and raised its full-year guidance.
The reason lies in the company’s expectations for its vaccines business. GSK’s respiratory syncytial virus (RSV) vaccine Arexvy, which rapidly...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?